| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A novel natural product, britanin, inhibits tumor growth of pancreatic cancer by suppressing nuclear factor-κB activation
|
Li, Ke
|
|
|
85 |
4 |
p. 699-709
|
artikel
|
| 2 |
Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia
|
Goto, Hiroaki
|
|
|
85 |
4 |
p. 773-783
|
artikel
|
| 3 |
Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma
|
Rodgers, Louis T.
|
|
|
85 |
4 |
p. 827-830
|
artikel
|
| 4 |
Docetaxel-loaded ultrasmall nanostructured lipid carriers for cancer therapy: in vitro and in vivo evaluation
|
Li, Min
|
|
|
85 |
4 |
p. 731-739
|
artikel
|
| 5 |
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer
|
Yamaguchi, Ou
|
|
|
85 |
4 |
p. 761-771
|
artikel
|
| 6 |
Evaluating primary intra-arterial chemotherapy versus intravenous plus intra-arterial chemotherapy for advanced intraocular retinoblastoma
|
Chen, Qiuying
|
|
|
85 |
4 |
p. 723-730
|
artikel
|
| 7 |
Impact of tumour size measurement inter-operator variability on model-based drug effect evaluation
|
Lombard, Aurélie
|
|
|
85 |
4 |
p. 817-825
|
artikel
|
| 8 |
Involvement of ER stress and reactive oxygen species generation in anti-cancer effect of CKD-516 for lung cancer
|
Kim, Soo Jin
|
|
|
85 |
4 |
p. 685-697
|
artikel
|
| 9 |
Metabolism and pharmacokinetics characterization of metarrestin in multiple species
|
Padilha, Elias C.
|
|
|
85 |
4 |
p. 805-816
|
artikel
|
| 10 |
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up
|
Pothuri, Bhavana
|
|
|
85 |
4 |
p. 741-751
|
artikel
|
| 11 |
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
|
Tolcher, Anthony W.
|
|
|
85 |
4 |
p. 673-683
|
artikel
|
| 12 |
Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic–pharmacodynamic model in gastrointestinal cancer patients
|
Arshad, Usman
|
|
|
85 |
4 |
p. 711-722
|
artikel
|
| 13 |
Repair of DNA damage induced by the novel nucleoside analogue CNDAG through homologous recombination
|
Liu, Xiaojun
|
|
|
85 |
4 |
p. 661-672
|
artikel
|
| 14 |
Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer
|
Keum, Jiyoung
|
|
|
85 |
4 |
p. 651-659
|
artikel
|
| 15 |
SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome
|
Liao, Xin
|
|
|
85 |
4 |
p. 785-792
|
artikel
|
| 16 |
The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats
|
Mayo, Bronwen J.
|
|
|
85 |
4 |
p. 793-803
|
artikel
|
| 17 |
The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients
|
Benoist, Guillemette E.
|
|
|
85 |
4 |
p. 753-760
|
artikel
|
| 18 |
The role of deubiquitinating enzymes in cancer drug resistance
|
Tanguturi, Parthasaradhireddy
|
|
|
85 |
4 |
p. 627-639
|
artikel
|
| 19 |
Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma
|
Reni, Michele
|
|
|
85 |
4 |
p. 641-650
|
artikel
|
Tijdschrift beschrijving